Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for Patients With EGFR Positive Advanced Solid Tumors

NCT03182816 is registered in ClinicalTrials.gov with Shanghai Cell Therapy Research Institute as lead sponsor.

NCT NCT03182816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03182816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for Patients With EGFR Positive Advanced Solid Tumors
Lead sponsor
Shanghai Cell Therapy Research Institute
Phase
Phase 1/2
Overall status
Unknown status
Start date
June 7, 2017
Completion date
April 20, 2019
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor